Key facts
- It has raised $3.3M across 2 recorded rounds; the latest was Seed Round ($250K) in May 2025.
- Notable investors include ENKORE International Enterprises, UF Innovate Ventures, University of Florida.
- iOncologi has filed 2 Form Ds with the SEC, most recently May 2025 ($250K sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for iOncologi
Funding rounds
2 roundsAbout iOncologi
Operator of a biotechnology company intended to focus on novel immunotherapies for the treatment of refractory cancers and infectious diseases. The company specializes in the use of intravenously delivered stem cells to overcome resistance to immune checkpoint inhibitors and holds particular expertise in the treatment of malignant brain tumors, enabling adult and pediatric patients with malignant gliomas to get advanced immunomodulatory stem cell therapy for speedy recovery.
- Sector
- Healthcare
- HQ
- Gainesville, FL, United States
- Founded
- 2017
- Employees
- 3
- Website
- ioncologi.com/
- Ownership
- Privately Held (backing)
iOncologi doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iOncologi shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iOncologi in its N-PORT filings yet. We sweep new filings monthly.